1 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Scancell Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer Modi-1 Moditope, Pembrolizumab, MicronJet600™ microneedle device (NanoPass) - Triple Negative Breast Cancer, Renal Cell Cancer | Phase 1 / Phase 2 | Recruiting | Scancell Ltd | 168 | 2022-04-07 | 2025-09-17 |
| A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection, COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection, COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants - COVID-19 | Phase 1 | Unknown | Scancell Ltd | 80 | 2021-10-01 | 2022-11-25 |
| SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) SCIB1 or iSCIB1+ DNA vaccine - Malignant Melanoma, Melanoma (Skin) | Phase 2 | Active not recruiting | Scancell Ltd | 173 | 2019-08-19 | 2025-12-19 |
| Study of a DNA Immunotherapy to Treat Melanoma SCIB1 - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | Scancell Ltd | 35 | 2010-05-01 | 2017-08-21 |
Melanoma (3) · COVID-19 (1) · Carcinoma, Renal Cell (1) · Skin Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Ipilimumab (1) · Nivolumab (1) · pembrolizumab (1)
United Kingdom (4) · South Africa (1) · United States (1)
Christian Ottensmeier, MD (2) · Hardev Pandha, MD (1) · Maria Marples, MD (1) · Paul Lorigan, MD (1) · Poulam M Patel, MD (1) · Poulam Patel (1) · Rodney Dawson, MD (1)